Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18433467 | TRADITIONAL CHINESE MEDICINE MIXTURE AND TRADITIONAL CHINESE MEDICINE EFFECTIVE INGREDIENT COMPOUND WITH FUNCTION OF PROMOTING DIRECTIONAL DIFFERENTIATION OF STEM CELLS INTO CARDIOMYOCYTES, AND APPLICATIONS THEREOF | February 2024 | October 2024 | Allow | 9 | 2 | 0 | No | No |
| 17945816 | ANTI-LESION STORAGE METHOD AND STORAGE SYSTEM FOR CELLS, TISSUES OR ORGANS | September 2022 | March 2025 | Allow | 30 | 3 | 0 | Yes | No |
| 17586587 | METHOD OF SCREENING CO2-ASSIMILATING MICROORGANISM | January 2022 | September 2024 | Allow | 31 | 2 | 0 | Yes | No |
| 17532917 | VISUAL CELL SORTING | November 2021 | January 2025 | Allow | 38 | 2 | 1 | No | No |
| 17523755 | METHODS TO IMPROVE SITE-DIRECTED INTEGRATION FREQUENCY | November 2021 | August 2024 | Allow | 33 | 1 | 1 | No | No |
| 17605888 | Adult Liver Progenitor Cells for Treating Non-Alcoholic Fatty Liver Disease | October 2021 | February 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17503443 | DIFFERENTIATED AND NONDIFFERENTIATED MSC COMPOSITIONS AND USE THEREOF | October 2021 | June 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17604088 | CELL CULTURE DEVICE AND USE OF SAME | October 2021 | June 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17603840 | METHODS AND COMPOSITIONS FOR TRANSGENE EXPRESSION | October 2021 | May 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17602072 | Treatment of Microvascular Disorders with Mesenchymal Stem Cells and Their Exosomes | October 2021 | May 2025 | Abandon | 43 | 1 | 1 | No | No |
| 17594202 | DMSO-FREE CRYOPRESERVATION SOLUTION AND PREPARATION METHOD AND USE THEREOF | October 2021 | June 2025 | Allow | 44 | 1 | 1 | No | No |
| 17483950 | NUCLEIC ACID CONSTRUCTS AND GENE THERAPY VECTORS FOR USE IN THE TREATMENT OF WILSON DISEASE | September 2021 | March 2025 | Allow | 41 | 1 | 0 | Yes | No |
| 17438229 | GENE THERAPY COMPOSITIONS AND METHODS FOR TREATING PARKINSON'S DISEASE | September 2021 | January 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17437411 | SPHEROID CULTURE METHOD FOR NEURAL STEM CELL | September 2021 | November 2024 | Allow | 38 | 1 | 0 | Yes | No |
| 17461209 | COMPOSITION FOR INCREASING BIOLOGICAL ACTIVITY OF STEM CELLS USING MIXTURE 4F | August 2021 | May 2025 | Allow | 44 | 2 | 1 | Yes | No |
| 17405230 | NATURAL KILLER CELLS EXHIBITING INCREASED ANTICANCER ACTIVITY AND IMMUNOTHERAPEUTIC USE THEREOF | August 2021 | January 2025 | Allow | 41 | 1 | 1 | No | No |
| 17430364 | TRANSGENIC MOUSE MODELS SUPPORTING INNATE IMMUNE FUNCTION | August 2021 | May 2025 | Allow | 45 | 1 | 1 | No | No |
| 17428587 | METHOD FOR MESENCHYMAL STEM CELL ISOLATION AND OSTEOBLAST DIFFERENTIATION | August 2021 | April 2025 | Allow | 45 | 1 | 1 | Yes | No |
| 17426014 | CLOT ADHESION PREVENTING AGENT AND BLOOD COLLECTION CONTAINER | July 2021 | May 2025 | Allow | 46 | 2 | 1 | No | No |
| 17426092 | GENETIC CONSTRUCT AND USES THEREOF | July 2021 | April 2025 | Abandon | 45 | 1 | 1 | No | No |
| 17417802 | CULTURE MEDIUM FOR INDUCING INCREASE IN PLASMID COPY NUMBER AND USE THEREOF | June 2021 | October 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17312191 | COMPOSITIONS AND METHODS FOR MODIFYING A TARGET NUCLEIC ACID | June 2021 | March 2025 | Allow | 45 | 1 | 1 | Yes | No |
| 17299413 | CRISPR GUIDE-RNA EXPRESSION STRATEGIES FOR MULTIPLEX GENOME ENGINEERING | June 2021 | November 2024 | Abandon | 42 | 1 | 0 | No | No |
| 17293653 | ANIMAL MODEL OF MUCOPOLYSACCHARIDOSES TYPE IVA | May 2021 | December 2024 | Allow | 43 | 2 | 1 | No | No |
| 17317700 | GENERATING NUCLEIC ACIDS WITH MODIFIED BASES USING RECOMBINANT TERMINAL DEOXYNUCLEOTIDYL TRANSFERASE | May 2021 | September 2024 | Allow | 40 | 2 | 1 | Yes | No |
| 17291963 | ANTI-GPC3 CHIMERIC ANTIGEN RECEPTORS (CARs) IN COMBINATION WITH TRANS CO-STIMULATORY MOLECULES AND THERAPEUTIC USES THEREOF | May 2021 | December 2024 | Abandon | 43 | 0 | 1 | No | No |
| 17289047 | AN ASPERGILLUS MICROORGANISM CARRYING DISRUPTIONS OF MULTIPLE GENES AND A METHOD OF PRODUCING THEREOF | April 2021 | January 2025 | Allow | 44 | 1 | 0 | Yes | No |
| 17283833 | VECTORS | April 2021 | November 2024 | Abandon | 43 | 0 | 1 | No | No |
| 17282846 | GENETICALLY MODIFIED STERILE AVIANS AND METHOD FOR THE RECONSTITUTION THEREOF | April 2021 | January 2025 | Allow | 46 | 1 | 1 | No | No |
| 17280369 | METHODS AND COMPOSITIONS FOR INCREASING PROTEIN EXPRESSION AND/OR TREATING A HAPLOINSUFFICIENCY DISORDER | March 2021 | December 2024 | Allow | 45 | 1 | 1 | No | No |
| 17274404 | Colostrum Derived Stem Cells, Neural Differentiation, Compositions and Supplements for Enhancing Mammalian Health | March 2021 | November 2024 | Allow | 45 | 1 | 0 | Yes | No |
| 17195625 | METHOD FOR GENE EDITING | March 2021 | July 2024 | Allow | 41 | 1 | 0 | No | No |
| 17269527 | IN SITU GENE EDITING | February 2021 | July 2025 | Allow | 52 | 3 | 1 | Yes | No |
| 17264763 | LDLR NEGATIVE PACKAGING CELL LINE FOR THE PRODUCTION OF VSV-G PSEUDOTYPED RETROVIRAL VECTOR PARTICLES OR VIRUS PARTICLES THEREOF | January 2021 | December 2024 | Allow | 47 | 1 | 1 | No | No |
| 17148477 | DNA DAMAGE RESPONSE SIGNATURE GUIDED RATIONAL DESIGN OF CRISPR-BASED SYSTEMS AND THERAPIES | January 2021 | November 2024 | Allow | 46 | 2 | 0 | Yes | No |
| 17054108 | Cell Culture Medium | November 2020 | June 2024 | Allow | 43 | 1 | 1 | Yes | No |
| 17073862 | ADENO-ASSOCIATED VIRUS COMPOSITIONS FOR RESTORING PAH GENE FUNCTION AND METHODS OF USE THEREOF | October 2020 | October 2024 | Allow | 48 | 1 | 1 | Yes | No |
| 16886129 | ENGINEERED DNA BINDING PROTEINS | May 2020 | February 2024 | Allow | 45 | 0 | 1 | Yes | No |
| 16758752 | SYSTEMS AND METHODS FOR TREATING HYPER-IGM SYNDROME | April 2020 | September 2024 | Allow | 53 | 2 | 1 | Yes | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner GU, QINHUA works in Art Unit 1633 and has examined 38 patent applications in our dataset. With an allowance rate of 71.1%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 44 months.
Examiner GU, QINHUA's allowance rate of 71.1% places them in the 26% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by GU, QINHUA receive 1.16 office actions before reaching final disposition. This places the examiner in the 18% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by GU, QINHUA is 44 months. This places the examiner in the 2% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +50.0% benefit to allowance rate for applications examined by GU, QINHUA. This interview benefit is in the 94% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 50.0% of applications are subsequently allowed. This success rate is in the 97% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 54.5% of cases where such amendments are filed. This entry rate is in the 76% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants file petitions regarding this examiner's actions, 200.0% are granted (fully or in part). This grant rate is in the 99% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.